Notice of Intent to Award a Blanket Purchase Agreement to a Single Firm for Sterilely Compounded Pharmaceuticals via 503B Compounding Pharmacies for Gallup Indian Medical Center IRC-GSUT2-20260002
Summary
AI-generated · Jan 14, 2026Provide sterilely compounded pharmaceuticals from an FDA-designated 503B facility on an as-needed basis under a single Blanket Purchase Agreement with Fagron Compounding Services LLC (dba Fagron Sterile Services). Items include Phenylephrine 100 mcg/mL, Succinylcholine 20 mg/10 mL, LET 5 mL syringe, Oxytocin 30 units in 500 mL (sterile to sterile and API), and Epinephrine 8 mg per 250 mL bag (or other strengths/volumes of the same medications in IV bags as required). Products must be sterilely compounded in an FDA-approved facility and have a beyond-use date of at least 30 days from manufacture.
The BPA is intended to be awarded to a single firm, based on the finding that this vendor is the only source capable of meeting the requirement. The arrangement will support multiple on-demand purchases during the base period and four successive option years. Vendors who believe they can fulfill the requirement may submit capability statements, price lists, and catalogs for consideration, though this notice does not solicit quotes. If additional BPAs are later determined to be in the government’s best interest, capable vendors may be contacted to establish a BPA.
The Navajo Area Indian Health Service, Gallup Service Unit in Gallup, NM, intends to award a single Blanket Purchase Agreement (BPA) with Fagron Compounding Services LLC (UEI: F7QNV46N18Q4) doing business as Fagron Sterile Services for sterilely compounded pharmaceuticals from an FDA-designated 503B facility on an as-needed basis. Items include Phenylephrine 100mcg.ml, Succinylcholine 20mg/10ml, LET 5ml syringe, Oxytoxin 30 units in 500ml (sterile to sterile and API), Epinephrine 8mg per 250ml bag (or other strength/volumes of the same medications in IV bags as available and required on an as-needed basis). Products must be sterilely compounded in an FDA approved facility with a beyond use date of at least 30 days from manufacture. The anticipated period of performance is: Base Period: 2/1/2026-1/31/2027 Option Period One: 2/1/2027-1/31/2028 Option Period Two: 2/1/2028-1/31/2029 Option Period Three: 2/1/2029-1/31/2030 Option Period Four: 2/1/2030-1/31/2031 The applicable North American Industry Classification System (NAICS) code assigned to this procurement is 325412- Pharmaceutical Preparation Manufacturing with a small business size standard of 1,300 employees. No further awards will be made unless the need for Gallup Indian Medical Center changes. The prospective BPA identified in this notice is sufficient at this time. The identified vendor has the capability to provide sterilely compounded pharmaceuticals in a 503B facility and market research indicates the vendor is the only source. In accordance with Part 12.201-1(e)(3)(i)(B), BPAs may be established with a single firm from which numerous individual purchases at or below the simplified acquisition threshold will likely be made in a given period. Any other sources that believe they are capable of fulfilling the government requirements as described are encouraged to submit their capability statement, price lists, and catalogs to the point of contact below via email only and no later than 1/28/2026 at 10:00AM (MST). In the event additional BPAs are deemed to be in the best interest of the government, capable vendors may be contacted and be requested to establish a BPA with the Government. This notice of intent is not a request for quotations and a solicitation will not be issued. Primary Point of Contact: Rodney Brown, Contract Specialist Email: Rodney.Brown@ihs.gov
From Special Notice posted on Jan 13, 2026Notice history
1-
Special Notice LATEST Posted Jan 13, 2026
Details
Award Information
Not yet awarded
Contacts
Agency
Place of Performance
USA